Methodology
Practical PCR genotyping protocols for Plasmodium vivax using Pvcs and Pvmsp1
-
* Corresponding author: Mallika Imwong noi@tropmedres.ac
1 Department of Clinical Tropical medicine, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
2 Département d'Immunologie, INSERM U567, CNRS UMR8104, Institut Cochin, Université René Descartes, Paris 75014, France
3 Laboratoire Commun de Séquençage, Institut Cochin, Université René Descartes, Paris 75014, France
4 Wellcome Unit, Faculty of Tropical Medicine, Mahidol University, Bangkok, Thailand
5 Centre for Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, UK
6 Unité de Parasitologie Bio-Médicale, CNRS URA2851, Institut Pasteur, Paris, France
7 Parasitologie Comparée et Modèles Expérimentaux USM307, CNRS IFR101, Muséum National d'Histoire Naturelle, CP52, 61 Rue Buffon, 75231 Paris Cedex 05, Paris, France
Malaria Journal 2005, 4:20 doi:10.1186/1475-2875-4-20
Published: 27 April 2005Abstract
Background
Plasmodium vivax is the second most prevalent malaria parasite affecting more than 75 million people each year, mostly in South America and Asia. In addition to major morbidity this parasite is associated with relapses and a reduction in birthweight. The emergence and spread of drug resistance in Plasmodium falciparum is a major factor in the resurgence of this parasite. P. vivax resistance to drugs has more recently emerged and monitoring the situation would be helped, as for P. falciparum, by molecular methods that can be used to characterize parasites in field studies and drug efficacy trials.
Methods
Practical PCR genotyping protocols based on polymorphic loci present in two P. vivax genetic markers, Pvcs and Pvmsp1, were developed. The methodology was evaluated using 100 P. vivax isolates collected in Thailand.
Results and Discussion
Analysis revealed that P. vivax populations in Thailand are highly diverse genetically, with mixed genotype infections found in 26 % of the samples (average multiplicity of infection = 1.29). A large number of distinguishable alleles were found for the two markers, 23 for Pvcs and 36 for Pvmsp1. These were generally randomly distributed amongst the isolates. A total of 68 distinct genotypes could be enumerated in the 74 isolates with a multiplicity of infection of 1.
Conclusion
These results indicate that the genotyping protocols presented can be useful in the assessment of in vivo drug efficacy clinical trials conducted in endemic areas and for epidemiological studies of P. vivax infections.